CompanyGraph
4D Molecular Therapeutics, Inc.
FDMT · United States
4dmoleculartherapeutics.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
799.38MUSDvs all stocks (USD)
Revenue (TTM)
92.01MUSDvs all stocks (USD)
Profit Margin
-194.74%vs Biotechnology peers
Beta
2.73xvs all stocks
52-Week Change
73.29%vs all stocks
Market Capitalization
799.38MUSDvs all stocks (USD)
Enterprise Value
477.27MUSDvs all stocks (USD)
Forward P/E
-3.54xvs Biotechnology peers
Price to Sales (TTM)
8.69xvs Biotechnology peers
Price to Book (MRQ)
1.96xvs Biotechnology peers
Enterprise to Revenue
5.19xvs Biotechnology peers
Enterprise to EBITDA
-2.53xvs Biotechnology peers
Profit Margin
-194.74%vs Biotechnology peers
Operating Margin
-2037.16%vs Biotechnology peers
Return on Assets (TTM)
-25.09%vs Biotechnology peers
Return on Equity (TTM)
-43.25%vs Biotechnology peers
Revenue (TTM)
92.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.42USDUpdated Sep 27, 2026Quarterly Revenue Growth
25106.70%vs Biotechnology peers
Gross Profit (TTM)
-145.10MUSDvs all stocks (USD)
EBITDA (TTM)
-188.89MUSDvs all stocks (USD)
Net Income (TTM)
-179.18MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
25106.67%vs Biotechnology peers
Operating Cash Flow (TTM)
-156.07MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-90.77MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
85.21MUSDFY2025 · Dec 31, 2025Operating Income
-159.55MUSDvs all stocks (USD)
Pre-tax Income
-140.11MUSDFY2025 · Dec 31, 2025Net Income
-140.11MUSDFY2025 · Dec 31, 2025EBIT
-159.55MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-151.92MUSDFY2025 · Dec 31, 2025Research & Development
195.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
49.06MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
19.48MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-140.11MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-112.02MUSDFY2025 · Dec 31, 2025Free Cash Flow
-112.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
60.24MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-140.11MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
7.63MUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.02MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.77MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.33MUSDFY2025 · Dec 31, 2025Capital Expenditures
-536.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-442.82MUSDFY2025 · Dec 31, 2025Sale of Investments
350.38MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-92.97MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
110.72MUSDFY2025 · Dec 31, 2025Shares Outstanding
55.21MSharesUpdated Sep 27, 2026Float Shares
42.49MSharesUpdated Sep 27, 2026Shares Short
12.01MSharesUpdated Sep 27, 2026Short Ratio
10.88daysvs all stocks
Short % of Shares Outstanding
24.92%vs all stocks
% Held by Insiders
2.93%vs all stocks
% Held by Institutions
105.91%vs all stocks
Total Cash (MRQ)
361.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.54USDUpdated Sep 27, 2026Total Debt (MRQ)
39.22MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0962xvs Biotechnology peers
Current Ratio (MRQ)
8.03xvs Biotechnology peers
Book Value per Share (MRQ)
7.38USDUpdated Sep 27, 2026Total Assets
566.71MUSDvs all stocks (USD)
Total Current Assets
413.13MUSDFY2025 · Dec 31, 2025Total Liabilities
61.05MUSDFY2025 · Dec 31, 2025Total Non-current Assets
153.58MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
17.06MUSDFY2025 · Dec 31, 2025Total Current Liabilities
43.98MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
60.24MUSDFY2025 · Dec 31, 2025Other Short-term Investments
342.41MUSDFY2025 · Dec 31, 2025Accounts Payable
11.16MUSDFY2025 · Dec 31, 2025Short-term Debt
5.59MUSDFY2025 · Dec 31, 2025Deferred Revenue
360.00KUSDFY2025 · Dec 31, 2025Long-term Debt
15.82MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
138.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-716.30MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
505.66MUSDvs all stocks (USD)
52-Week Low
6.96USDUpdated Sep 27, 202652-Week High
16.93USDUpdated Sep 27, 202652-Week Change
73.29%vs all stocks
Beta
2.73xvs all stocks
50-Day MA
13.09USDUpdated Sep 27, 2026200-Day MA
10.36USDUpdated Sep 27, 2026Avg 10-Day Volume
1.10MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.11MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-2.63USDUpdated Sep 27, 2026Other Income / Expense
-37.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Altman Z-Score 6.09: safe zoneNotable
Altman Z-Score: 6.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule